The HEXA Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HT29 colorectal adenocarcinoma cells with disrupted HEXA gene function. This model provides a loss-of-function tool for studying the alpha subunit of beta-hexosaminidase A in glycosphingolipid metabolism and lysosomal homeostasis, without clonal selection, thus preserving population-level heterogeneity.
HT29 cells originate from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female. These adherent epithelial cells retain tumorigenic properties along with absorptive and secretory functions typical of intestinal epithelium, making them a widely used model for drug absorption and cancer research.
HEXA encodes the alpha subunit of the lysosomal enzyme beta-hexosaminidase A, which forms a heterodimeric complex with the beta subunit (HEXB) to cleave terminal N-acetyl-D-galactosamine residues from GM2 ganglioside. This catabolic step, facilitated by the GM2 activator protein (GM2A), is essential for lysosomal ganglioside degradation and is regulated upstream by transcription factors such as TFEB and CREB, which respond to cellular stress signals. Disruption of HEXA leads to GM2 ganglioside accumulation, subsequently affecting the metabolism of downstream sphingolipids including GM3, ceramide, sphingosine, and sphingosine-1-phosphate. These alterations perturb sphingolipid signaling networks and lysosomal function, impacting lipid homeostasis and potentially affecting cellular processes such as proliferation and survival.
In the HT29 colorectal adenocarcinoma model, HEXA knockout provides a unique system to dissect the interplay between lysosomal storage pathology and tumor cell biology. Intestinal epithelial cells, with their high metabolic activity, are particularly dependent on efficient lysosomal turnover for maintaining barrier integrity and homeostasis. HEXA deficiency in these cells may alter ganglioside-dependent signaling pathways that influence migration, apoptosis, and drug responsiveness, thereby offering insights into the role of glycosphingolipid metabolism in colorectal cancer progression. Additionally, this model permits investigation of how lysosomal dysfunction impacts epithelial cell behavior in the gastrointestinal context.
The HEXA Knockout HT29 Polyclonal Cells are suitable for a range of applications, including in vitro modeling of Tay-Sachs disease and GM2 gangliosidosis type I, elucidation of lysosomal storage disorder mechanisms, and functional studies of gangliosides in colorectal cancer. Validated assays include Western blotting and RT-qPCR for confirming HEXA disruption, immunofluorescence and mass spectrometry for quantifying GM2 accumulation, enzyme activity measurements, LysoTracker staining for lysosomal analysis, and functional assays such as migration and apoptosis. This polyclonal model also serves as a robust platform for drug screening targeting sphingolipid metabolism or enhancing lysosomal function. For additional technical information, please contact Ascent Research.
